NEW YORK (GenomeWeb News) – Bruker reported today that its revenues in the third quarter were down 4 percent year over year, falling to $419.8 million from $439 million in Q3 2013.

It missed analysts' consensus estimates on the top and bottom line, leading to a 12 percent decline in its share price to $18.35 in early Friday trade on the Nasdaq.

The drop in revenues was driven by weakness in demand for the company's NMR, semiconductor, and data storage products, President and CEO Frank Laukien said on a conference call following the earnings release.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.